Abstract
Chronic hepatitis B (CHB) and treatment may be associated with increased risk of osteopenia/osteoporosis. Here, we review the prevalence of osteopenia/osteoporosis among patients with CHB and the effect of antiviral therapy on bone density. We also highlight screening and management strategies for bone disease among patients with CHB. While there are concerns with first-line antiviral therapy such as tenofovir disoproxil fumarate in the development of osteopenia/osteoporosis, the available data remain rather unclear. However, with the development of tenofovir alafenamide, these concerns may be mitigated. At present, EASL recommends dual-energy X-ray absorption (DEXA) scans for patients with osteoporotic risk factors, with a repeat DEXA scan based upon baseline findings. Patients with CHB have higher incidence and prevalence of osteopenia/osteoporosis compared with patients without CHB. Further studies are needed to understand the impact of antiviral therapy on bone therapy, and more CHB specific recommendations are needed for bone health management.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
